Selective localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in B 16 melanoma.
The acridine derivative 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA, NSC-141549), a new antitumor agent undergoing phase I clinical evaluation, is highly active against B16 melanoma in vivo. AMSA was found to be concentrated in B16 melanoma cells in vivo and remained at high concentrations for at least 72 h. Subcellular fractionation of B16 melanoma cells revealed the drug to be bound to melanin granules. The results suggest the possible use of AMSA in human melanoma and the design of other antimelanoma agents that would exploit the affinity of the acridine nucleus for melanin.
D000166:Acridines / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D004353:Drug Evaluation, Preclinical; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism; D008698:Mesylates / Q000378:metabolism / Q000627:therapeutic use*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism; D013997:Time Factors
D000166:Acridines; D000970:Antineoplastic Agents; D008698:Mesylates